$IMDX 8-K SEC Filings

Filed On	Filing
21 Sep 2026	8-K: Entry into a Material Definitive Agreement This AMENDMENT NO. 2 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER, dated as of September 15, 2026 (this “Amendment No. 2”), is entered into by and between Insight Molecular Diagnostics Inc. (formerly known as Oncocyte Corporation...
10 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
17 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
13 May 2026	8-K: Results of Operations and Financial Condition
30 Apr 2026	8-K: Other Events
26 Mar 2026	8-K: Results of Operations and Financial Condition
26 Feb 2026	8-K: Entry into a Material Definitive Agreement
12 Feb 2026	8-K: Entry into a Material Definitive Agreement; Other Events
11 Feb 2026	8-K: Regulation FD Disclosure
10 Nov 2025	8-K: Results of Operations and Financial Condition
02 Oct 2025	8-K: Departure/Election of Directors or Officers; Compensation
19 Sep 2025	8-K: Departure/Election of Directors or Officers; Compensation
11 Aug 2025	8-K: Results of Operations and Financial Condition
02 Jul 2025	8-K: Submission of Matters to a Vote of Security Holders
17 Jun 2025	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
12 May 2025	8-K: Results of Operations and Financial Condition
17 Apr 2025	8-K: Changes in Registrant's Certifying Accountant
24 Mar 2025	8-K: Results of Operations and Financial Condition
10 Mar 2025	8-K: Departure/Election of Directors or Officers; Compensation
10 Feb 2025	8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

Comments